logo
logo

Accelmed Partners Raises $400 Million to Invest in Commercial Stage HealthTech

Mar 17, 2021•over 4 years ago

Amount Raised

$400 Million

Needham

Description

Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies, today announced the successful close of its oversubscribed second fund, Accelmed Fund II, LP (“Fund II” or the “Fund”) at the Fund’s hard cap of $400 million, exceeding its original $300 million target. Fund II received significant backing from new investors globally, including pension funds, insurers, family offices, and high net worth individuals, as well as from existing Accelmed limited partners.

Company Information

Company

Accelmed Partners

Location

Needham, Alabama, United States

About

Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies. Since 2009, Accelmed has deployed over $400 million into companies spanning medical devices, diagnostics, digital health and technology-enabled healthcare services. Led by Founder and Managing Partner Dr. Uri Geiger, together with General Partners Evan Norton, Lior Shav and Dr. Rafael Torgovicky, Accelmed seeks to accelerate value and scale innovation across the HealthTech field by bringing to bear the team’s industry experience, operational and financial expertise, and strong global relationships. For more information, please visit https://www.accelmed.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech